Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Multidrug-Resistant Infections Rising in Children

By Rush University | May 14, 2018

Antibiotic-resistant Acinetobacter baumannii infections, one of the most common hospital-acquired infections in children across the United States, are on the rise, according to results of a recent study published in the Journal of the Pediatric Infectious Diseases Society on March 22.

“Acinetobacter are bacteria known to cause serious infections and notoriously difficult to treat because of growing antibiotic resistance. The bacteria survive for long periods in the environment,” said study primary author Dr. Latania Logan, chief of pediatric infectious diseases and associate professor of pediatrics at Rush University Medical Center.

The research examined national and regional trends of antibiotic resistance in clinical specimens over a 13-year period. The data was taken from The Surveillance Network Database, a network of 300 laboratories distributed throughout the U.S. and is compiled by the Centers for Disease Dynamics Economics and Policy in Washington, D.C.

Children with Chronic Conditions at Higher Risk
Because A. baumannii is an infection caused by bacteria that takes advantage of patients with compromised immune systems, children with a chronic condition are at a higher risk of infections of the lung, urinary tract, or other sites after surgery, intubation, trauma, or catheterization.

The amount of A. baumannii samples in infected children that were resistant to the antibiotics cephalosporin and carbapenem increased between 1999 and 2012 overall. However, the authors of the study noted a slight decline after a peak in 2008. Antibiotic stewardship guidelines released in 2007 or infection control guidance specifically designed to combat multi-drug resistant A. baumannii in health care settings may have been related to the decrease.

“While we are encouraged by the slight downtrend in resistance after 2008, there is still an overall increase in these infections. Further studies are needed to assess the most effective prevention strategies in children,” Logan said.

‘A Perfect Storm’ of Drug Resistant Infections
A. baumannii has numerous ways that protect it from antibiotics. The bacteria are able to protect themselves by using genetic adaptations that support survival in dry, harsh environments, and additionally have in place several mechanisms to render antibiotics ineffective. In this situation, “a perfect storm” results, Logan said. As a result, highly resistant A. baumannii infections are increasingly being reported worldwide.

The study results show that the number of cephalosporin resistant A baumannii increased from 13.2 percent of infections in 1999 to 23.4 percent in 2012, whereas the number of carbapenem resistant A. baumannii increased from 0.6 percent in 1999 to 6.1 percent in 2012. From 1999 to 2012, the proportion of cephalosporin resistant and carbapenem resistant bacteria among all A. baumannii increased each year by 3 percent and 8 percent, respectively After 2008, a downward trend was observed, but resistance remained higher than the 1999 baseline.

“It is encouraging to see the downtrend after 2008, but we need to continue to monitor,” said the study co-author Dr. Sumanth Gandra, a resident scholar in the Center For Disease Dynamics, Economics & Policy, an independent research initiative based in Washington, DC and New Delhi, India.

SOURCE: Rush University


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE